Skip to main content

Alterity Therapeutics Ltd

corporate_fare Company Profile

Alterity Therapeutics Ltd

ATHE·NASDAQ·Life Sciences·CIK 0001131343

ALTERITY THERAPEUTICS LTD is a development stage medical biotechnology company. The company is currently focused on research activities and has not yet commercialized any products. Since its inception, ALTERITY THERAPEUTICS LTD has experienced recurring losses. For the year ended June 30, 2026, the company reported a net loss of $23,400,949, compared to a net loss of $12,147,828 in the year ended June 30, 2025. The net operating cash outflow for the year ended June 30, 2026, was $22,523,333, compared to $11,451,248 in the year ended June 30, 2025. The company's primary expenses are related to research and development (R&D) and general and administration. R&D expenses mainly cover activities conducted by third parties on behalf of ALTERITY THERAPEUTICS LTD. These expenses also include costs for acquiring and developing patents, as well as salaries and fees for employees and consultants involved in R&D. During the 2026 financial year, ALTERITY THERAPEUTICS LTD successfully raised new equity funding to support its planned R&D programs for at least the next 12 months.

Alterity Therapeutics Ltd (NASDAQ:ATHE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for ATHE at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Formalizes 1-for-50 Reverse Stock Split, Details Timetable for Share Consolidation
  • Shareholders to Vote on 1-for-50 Reverse Stock Split and Significant Director Option Grants
  • Positive FDA Feedback Advances Alterity's ATH434 Phase 3 Program for MSA
  • Alterity Therapeutics Secures Positive FDA Feedback on Manufacturing for ATH434 Phase 3 Program
  • Substantial Holder's Percentage Ownership Drops, Signaling Significant Dilution

Financial Snapshot

Fiscal year ended June 30, 2026
Net Income
-$23.4M
Op. Cash Flow
-$22.52M
Free Cash Flow
-$22.52M
Cash & Equivalents
$37.32M
Debt / Equity
0.00×
Shares Outstanding
217.51M sh
Source: 20-F · filed 2026-08-28 · accession 0001437749-26-029135

Insider Transactions

ATHE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$4.05
52-week range · as of 2026-09-08 $2.66 – $5.89
Market cap
$75.37M
Volume
22.3K (1.4× avg)
3-mo avg 16.3K
Live data · 2026-09-13 21:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ATHE - Filings & News (Page 2)

ATHE
Apr 30, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.64
Real-time Price: $4.05 info
Change: -$0.590 (-13%) info
Market Cap: $75.368M info
ATHE
Apr 29, 2026, 8:10 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.58
Real-time Price: $4.05 info
Change: -$0.5299 (-12%) info
Market Cap: $75.368M info
ATHE
Apr 27, 2026, 7:25 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.44
Real-time Price: $4.05 info
Change: -$0.390 (-9%) info
Market Cap: $75.368M info
ATHE
Apr 27, 2026, 6:21 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $4.05 info
Change: -$0.450 (-10%) info
Market Cap: $75.368M info
ATHE
Apr 27, 2026, 6:21 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $4.05 info
Change: -$0.450 (-10%) info
Market Cap: $75.368M info
ATHE
Apr 22, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.09
Real-time Price: $4.05 info
Change: -$1.04 (-20%) info
Market Cap: $75.368M info
ATHE
Apr 17, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.97
Real-time Price: $4.05 info
Change: +$0.0799 (+2%) info
Market Cap: $75.368M info
ATHE
Apr 16, 2026, 6:06 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.46
Real-time Price: $4.05 info
Change: +$0.590 (+17%) info
Market Cap: $75.368M info
ATHE
Apr 15, 2026, 6:02 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $4.05 info
Change: +$0.5135 (+15%) info
Market Cap: $75.368M info
ATHE
Apr 01, 2026, 6:10 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.36
Real-time Price: $4.05 info
Change: +$0.6883 (+20%) info
Market Cap: $75.368M info
ATHE
Mar 30, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.15
Real-time Price: $4.05 info
Change: +$0.900 (+29%) info
Market Cap: $75.368M info
ATHE
Mar 19, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.45
Real-time Price: $4.05 info
Change: +$0.600 (+17%) info
Market Cap: $75.368M info
ATHE
Mar 04, 2026, 6:03 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.29
Real-time Price: $4.05 info
Change: +$0.760 (+23%) info
Market Cap: $75.368M info
ATHE
Feb 25, 2026, 6:19 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.43
Real-time Price: $4.05 info
Change: +$0.620 (+18%) info
Market Cap: $75.368M info
ATHE
Jan 30, 2026, 7:59 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.26
Real-time Price: $4.05 info
Change: +$0.790 (+24%) info
Market Cap: $75.368M info
ATHE
Jan 20, 2026, 9:56 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.09
Real-time Price: $4.05 info
Change: +$0.960 (+31%) info
Market Cap: $75.368M info
ATHE
Jan 15, 2026, 6:31 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.40
Real-time Price: $4.05 info
Change: +$0.650 (+19%) info
Market Cap: $75.368M info
ATHE
Jan 13, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.40
Real-time Price: $4.05 info
Change: +$0.650 (+19%) info
Market Cap: $75.368M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets